Literature DB >> 21537936

Second events following ductal carcinoma in situ of the breast: a register-based cohort study.

Ragnhild Sørum Falk1, Solveig Hofvind, Per Skaane, Tor Haldorsen.   

Abstract

The incidence of ductal carcinoma in situ (DCIS) of the breast has increased in recent decades, particularly, in counties offering mammography screening. The aims of the present study are to examine factors that may predict subsequent breast malignancy amongst patients with DCIS, and to compare the incidence of the subsequent malignancy and mortality with that of the general population. This population-based study includes all primary cases of pure DCIS diagnosed in Norway in the period 1993 to 2007 (N = 3167). The patients were followed to subsequent malignancy (DCIS or invasive cancer) or death. Risk estimates within 10 years of follow-up were calculated using Kaplan-Meier methods adjusting for competing risks, Cox regression models and Standard Incidence and Mortality Ratios. Patients with DCIS had a 11.2% risk of being diagnosed with a subsequent breast malignancy within 10 years (9.4% for invasive cancer), implying that they were five times as likely to be diagnosed with breast malignancy as the general female population in Norway. The risk was dependent on the treatment of the DCIS; patients treated with mastectomy and breast-conserving treatment had a 3.8 and 9.8% risk of ipsilateral invasive cancer within 10 years, respectively. Breast cancer mortality was 2.5% within 10 years of follow-up, a fourfold risk compared with the general population. Patients with DCIS have an increased risk of both subsequent breast malignancy and breast cancer death compared with women in the general population. Our results support previous knowledge of DCIS as a heterogeneous disease.

Entities:  

Mesh:

Year:  2011        PMID: 21537936     DOI: 10.1007/s10549-011-1531-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Authors:  Meghna S Trivedi; Austin M Coe; Alejandro Vanegas; Rita Kukafka; Katherine D Crew
Journal:  Cancer Prev Res (Phila)       Date:  2017-06-13

2.  Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ.

Authors:  Carina Strell; Janna Paulsson; Shao-Bo Jin; Nicholas P Tobin; Artur Mezheyeuski; Pernilla Roswall; Ceren Mutgan; Nicholas Mitsios; Hemming Johansson; Sarah Marie Wickberg; Jessica Svedlund; Mats Nilsson; Per Hall; Jan Mulder; Derek C Radisky; Kristian Pietras; Jonas Bergh; Urban Lendahl; Fredrik Wärnberg; Arne Östman
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

3.  Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.

Authors:  Meghan R Flanagan; Mara H Rendi; Vijayakrishna K Gadi; Kristine E Calhoun; Kenneth W Gow; Sara H Javid
Journal:  Ann Surg Oncol       Date:  2015-07-23       Impact factor: 5.344

Review 4.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

5.  Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.

Authors:  Brian L Sprague; Pamela M Vacek; Sally D Herschorn; Ted A James; Berta M Geller; Amy Trentham-Dietz; Janet L Stein; Donald L Weaver
Journal:  Breast Cancer Res Treat       Date:  2018-11-17       Impact factor: 4.872

6.  [Limits of mammography screening: current controversies and perspectives].

Authors:  K Hellerhoff
Journal:  Radiologe       Date:  2013-09       Impact factor: 0.635

7.  Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study.

Authors:  Brian L Sprague; Vicki McLaughlin; John M Hampton; Polly A Newcomb; Amy Trentham-Dietz
Journal:  Breast Cancer Res Treat       Date:  2013-08-25       Impact factor: 4.872

8.  Ductal carcinoma in situ: what can we learn from clinical trials?

Authors:  Lucio Fortunato; Igor Poccia; Ugo de Paula; Elena Santini
Journal:  Int J Surg Oncol       Date:  2012-05-09

9.  Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.

Authors:  Tae-Kyung Yoo; Sang Hyun Park; Kyung Do Han; Byung Joo Chae
Journal:  BMC Cancer       Date:  2021-06-26       Impact factor: 4.430

10.  Overdiagnosis among women attending a population-based mammography screening program.

Authors:  Ragnhild Sørum Falk; Solveig Hofvind; Per Skaane; Tor Haldorsen
Journal:  Int J Cancer       Date:  2013-02-25       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.